Translational genetics: advancing fronts for craniofacial health.

Scientific opportunities have never been better than today! The completion of the Human Genome project has sparked hope and optimism that cures for debilitating conditions can be achieved and tailored to individuals and communities. The availability of reference genome sequences and genetic variations as well as more precise correlations between genotype and phenotype have facilitated the progress made in finding solutions to clinical problems. While certain craniofacial and oral diseases previously deemed too difficult to tackle have benefited from basic science and technological advances over the past decade, there remains a critical need to translate the fruits of several decades' worth of basic and clinical research into tangible therapies that can benefit patients. The fifth Annual Fall Focused Symposium, "Translational Genetics - Advancing Fronts for Craniofacial Health", was created by the American Association for Dental Research (AADR) to foster its mission to advance interdisciplinary research that is directed toward improving oral health. The symposium showcased progress made in identifying molecular targets that are potential therapeutics for common and rare dental diseases and craniofacial disorders. Speakers focused on translational and clinical applications of their research and, where applicable, on strategies for new technologies and therapeutics. The critical needs to transfer new knowledge to the classroom and for further investment in the field were also emphasized. The symposium underscored the importance of basic research, chairside clinical observations, and population-based studies in driving the new translational connections needed for the development of cures for the most common and devastating diseases involving the craniofacial complex.

Evaluation of hypertensive males for primary coronary heart disease events using conventional risk factors and maximal exercise testing.

Whereas hypertension is a risk factor for primary coronary heart disease events, the relative contributions of other risk factors and abnormal responses to symptom-limited maximal exercise are not well-established. After 5.2 +/- 1.5 years of follow-up of 633 men with clinically-diagnosed hypertension based upon criteria of examining physicians (whether or not the men were currently treated for hypertension), 54 primary events were revealed. The annual coronary heart disease (CHD) event rate of 16.9/1000 men at risk was significantly higher than the annual rate of 3.6/1000 found for healthy men (p < 0.0001). Variables associated with increased risk were smoking cigarettes, risk factor count or tally, chest pain during exercise, percentage of functional aerobic impairment, and percentage heart rate impairment, the latter two variables suggesting early evidence of left ventricular dysfunction on strenuous exertion. Ischemic ST depression was not an important predictor. The three exercise variables were included in an exercise predictor count, and multivariate analysis revealed that this count and the risk factor count were the most important predictors of primary CHD events. Combining the risk factor count and the exercise predictor count, three groups with increasing risk of primary CHD events were identified. In those persons with both a risk factor count and exercise predictor count of zero, the annual rate was 7.3 events/1000 man-years; when either count was one or more, the rate was 15.5 events/1000 man-years; when both counts were one or more, the rate was 49.5 events/1000 man-years.